Aurobindo Pharma share news, announcements and annual reports
NSE: AUROPHARMABSE: 524804Pharmaceuticals & BiotechnologyMid Cap
Aurobindo Pharma Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 1995 on BSE, Jul 2000 on NSE
Last close ₹1,681.40up ₹21.50 (1.30%)BSE ₹1,677.80
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,659.90.
30 Oct: open ₹1,652.00, high ₹1,687.00, low ₹1,647.20
52-week range of traded prices to 30 Oct 2026
₹1,091.20Low, 30 Oct 2025₹1,740.00High, 24 Sep 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results and dividend. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹96,744 Cr138th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 26.06
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.55
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 10.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 11.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.20
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 9,52,65057.5% delivered
Aurobindo Pharma orders, deals and press releases
463 filed, newest first. Page 7 of 10.
Oct 2011
Sep 2011
Aug 2011
Jun 2011
May 2011
Apr 2011
Mar 2011
Feb 2011
Jan 2011
Dec 2010
30 Dec · Business
Compensation Committee of the Board at the meeting held on December 30, 2010 has made allotment of 2,700 Equity Shares of Rs.5/- each at a premium of Rs.357.60 per share under ESOP-2004 Scheme of the Company. Consequent to the allotment the paid up share capital of the Company has increased from 58221558 Equity Shares of Rs.5/- each to 58224258 Equity Shares of Rs.5/-each.
Nov 2010
Oct 2010
Sep 2010
Aug 2010
Jul 2010
19 Jul · Business
The Compensation Committee of the Board on July 19, 2010 has made allotment of 27,007 Equity Shares of Rs.5/- each at premium of Rs.357.60 per Share under ESOP-2004 Scheme of the Company. Consequent to the allotment the paid up share capital of the Company has increased from 56453157 Equity Shares of Rs.5/- each 56480164 Equity Shares of Rs.5/-each.
Jun 2010
8 Jun · Business
May 2010
18 May · Business
Apr 2010
29 Apr · Business
Pursuant to the approval of the Hon'ble High Court of Andhra Pardesh to the Scheme of Amalgamation of Trident Life Sciences Limited, wholly owned subsidiary with Aurobindo Pharma Limited, the Company is pleased to inform that the Scheme of Amalgamation is made effective on April 29, 2010. Further, no shares would be issued by the Company in consideration for the merger as Trident is a wholly owned subsidiary of the Company.16 Apr · Business
Press release dated April 16, 2010, titled " Aurobindo Pharma receives approvals for Cefprozil Tablets and PFOS from Health Canada" A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.13 Apr · Business
Press release dated April 13, 2010, titled " Aurobindo Pharma receives final approval for Ondansetron Orally Disintegrating Tablets" A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.8 Apr · Business
Press release dated April 08, 2010, titled " Aurobindo Pharma receives final approval for Venlafaxine Hydrochloride Tablets." A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Mar 2010
22 Mar · Business
Press release dated March 20, 2010, titled "Aurobindo Pharma receives approval for Topiramate Tablets from Health Canada". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.4 Mar · Business
Press release dated March 04, 2010, titled "Global Pharmaceutical Leader Aurobindo Presents AuroSource, its new division for Custom Research and Manufacturing (CRAMS)". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.3 Mar · Business
Press release dated March 03, 2010, titled "Aurobindo Pharma receives approval for Cefuroxime Axetil Tablets from Health Canada". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.